替换
查找内容:
替换为:
全部替换
插入链接
链接网址:
链接显示标题:
请选择网址类型
点我插入链接
插入文件
文件名称:
文件显示标题:
请选择文件类型
点我插入文件
发现错误 发表观点

原文内容

反馈意见

提交 正在提交..... 反馈历史

复制下面的地址分享给好友

确定 正在提交.....
train

你好,

关闭
提交 重做 重新开始 关闭
跳转
  • 新建同级
  • 新建子级
  • 删除
  • 重命名
选择收藏夹
新建收藏夹
公开

取消 确定

1. 基本信息
姓名:
企业:
职位:
联系方式:
邮箱:
2. 请在此填写您的问题,我们将优先安排答疑
提交

报名成功!
课程观看链接如下:
请添加课程助理微信,获得更多信息:
确认
确定
取消 确认

识林

  • 知识
  • 视频
  • 社区
  • 政策法规
    • 国内药监
    • FDA
    • EU
    • PIC/S
    • WHO
    • ICH
    • MHRA
    • PMDA
    • TGA
  • 研发注册
    • 概览
    • 监管动态
    • 研究专题
  • 生产质量
    • 概览
    • 监管动态
    • 各国GMP
    • 中国GMP
    • 中国GMP指南
    • GMP对比
    • 检查缺陷
    • 研究专题
  • 主题词库
  • 帮助中心
  • 关于识林
    • 识林介绍
    • 识林FAQs
    • 功能介绍
    • 团队诊断
    • 联系我们
  • 30天免登录

    忘记密码?

OGD发布2014财年最终统计数据

首页 > 资讯 > OGD发布2014财年最终统计数据

页面比对

出自识林

OGD发布2014财年最终统计数据
GDUFA绩效
页面比对
笔记

2014-10-09 Lachman CONSULTANTS

跳转到: 导航, 搜索

Activities Report of the Generic Drug Program (FY 2014)
随着仿制药办公室(OGD)收到的ANDA破纪录数量和近代破纪录的低批准数量,我们进入2015财年依旧在寻找亮点。2014财年OGD收到1473件ANDA,包括破月记录的635件和两个月各4件的低接收量。9月有25件ANDA提交。至于批准情况,整个财年的总批准件数刚刚超过400的目标,共406件。2014财年OGD还发布了91件暂时批准。

回顾完全回应函(CRL),9月为全年最低月有75件,仅比2013财年最低月份3月的73件多出2件。2014财年CRL总量仅比2013财年略高,各自为1254件比1251件…,但今年比上个财年有显著的人员增加。这很可能继续反映了培训新员工的高时间成本,以及培训负荷造成的效率低下。当培训周期接近结束时,效率很可能会提高,但企业还需要等待多久?

2014财年拒绝接收(RTR)的发布显著较高,173件相比2013财年107件。这很可能意味着2013财年年底公布的RTR标准的严格性增加。

2014财年CRL后GDUFA会议请求共计85次,举行了60次会议,总计85次的请求中仅8次拒绝、3次取消、11次未决、3次批准。会议请求平均似乎是每月5-6次。

虽然我不能肯定我在GDUFA第2年的这些数字中看到了很多好消息,第3年的指标可能会进入新的现实。让我们期望对第1和第2年的申请不收集指标的理由(因为增加雇佣和培训对资源的消耗),变为OGD军团准备好迎接GDUFA指标年的挑战。

另外一个有趣的消息是,预计2014年10月1日之后会出现另外一个申请提交高峰,企业可能在能够利用到第一个指标年的好处之前推迟提交。迄今为止,OGD还没有看到任何异常的繁忙。我们将继续跟进这一问题。原因之一是,这一繁忙尚不能与2014年6月的刺激因素相提并论,而且其他申请仍在等待生成(现在必需)6个月的加速和室温稳定性数据以提交文件。

总之,GDUFA的头两年让业界非常担忧。第3年可能是一个突破年,但OGD仍在公布剩余的招聘职位并整合到项目中。OGD正在聆听业界的忧虑,并试图解决,即使其中一些问题在GDUFA目标函之外。他们的成功取决于目标,但业界将密切关注进程中的更多迹象。

Lachman CONSULTANTS - Bob Pollock先生 2014-10-09
校译:识林-椒 2014-10-09

识林www.shilinx.com,版权所有,如需转载请注明出处

FY 2014 Final Statistics for OGD Released
Written by Bob Pollock • October 09, 2014

With a record number of ANDAs received by the Office of Generic Drugs (OGD) and a modern day record low number of approvals, we move into FY 2015 still looking for the bright spot. OGD received 1473 ANDAs for FY 2014, which included a record 635 monthly receipt record and two monthly low receipt records of 4. September saw 25 ANDA submitted. As far as approvals go, the total just surpassed the 400 mark at 406 for the full fiscal year. OGD also issued 91 tentative Approvals in FY 2014

In review of Complete Response Letters (CRL), September saw a monthly low of 75 for the year, which is only 2 more than the FY 2013 monthly low of 73 seen in March of 2013. CRL totals for FY 2014 were only slightly higher than FY 2013, with 1254 vs 1251 respectively….and this is with a significantly staffing increase over last FY. This is likely still reflective of the high time cost of training the new staff and the inefficiency that the training load creates. Productivity is likely going to increase as the training cycle comes to a close, but how long can industry wait for this to happen?

Refuse-to-Receive (RTR) issuances in FY 2014 were significantly higher, at 173 vs 107 for FY 2013. This likely signifies the increase stringency in RTR criteria announced at the end of FY 2013.

Post-CRL GDUFA meeting requests totaled 85 in FY 2014 with 60 meeting being held, only 8 denied and 3 cancelled and 11 pending, and a number of 3 granted rounds out the 85 total requests. Meeting requests appears to be averaging around 5-6 per month.

While I am not certain I see much good news in the number for year two of GDUFA, year three's metrics will likely kick in the new reality-let's hope the rationale for not collecting metrics on applications for year 1 and 2 (due to the ramp up in hiring and the drain on resources that training requires) translates into an OGD corps ready to meet the challenge of GDUFA's metric years.

One other interesting factoid is that we expected another rush after October 1, 2014 in application submissions for firms that may have delayed submission until then to take advantage of the first year of metrics. So far, according to OGD, they have not seen any abnormal rush. We will keep track of this issue. One reason that this rush has not yet been seen could be related to the big June 2014 push and other applications still waiting for the generation of the (now required) 6 months of accelerated and room temperature stability for filing.

All in all, the first two years of GDUFA have the industry very concerned. Year three may be a breakout year, but OGD still has the remaining hires to be brought on board and assimilated into the program. OGD is listening to industry concerns and is trying to address them, even though some of the issues are outside of the GDUFA goals letter. Their success is dictated by the goals but industry will be watching closely for even more signs of progress.

取自“https://login.shilinx.com/wiki/index.php?title=OGD%E5%8F%91%E5%B8%832014%E8%B4%A2%E5%B9%B4%E6%9C%80%E7%BB%88%E7%BB%9F%E8%AE%A1%E6%95%B0%E6%8D%AE”
上一页: 片剂生产商转向连续生产,QbD是基本要素
下一页: 【DMF】API_DMF备案完整性评价_(1)
相关内容
相关新闻
  • FDA发布2013年度GDUFA各项收费...
  • 仿制药使用费修订案GDUFA签署
  • FDA公布2013财年GDUFA绩效报告
  • FDA仿制药办公室2013及2014财...
  • 2014财年过半—ANDA提交和审评...
热点新闻
  • ICH 发布新 Q1 稳定性指南...
  • 【直播】25年4月全球法规月报...
  • 【识林新文章】中国无菌附录对...
  • 【识林新工具】AI知识助手,AI...
  • VHP(过氧化氢蒸汽)的“脆弱...

 反馈意见

Copyright ©2011-2025 shilinx.com All Rights Reserved.
识林网站版权所有 京ICP备12018650号-2 (京)网药械信息备字(2022)第00078号
请登录APP查看
打开APP